Private Advisory Group LLC Has $414,000 Position in Novo Nordisk A/S (NYSE:NVO)

Key Points

• Private Advisory Group LLC reduced its stake in Novo Nordisk A/S by 60.7% during the first quarter, holding 5,964 shares valued at approximately $414,000 by quarter's end.
• Shares of Novo Nordisk A/S rose $1.16 to $48.23, with the stock experiencing significant trading volume of 34,710,384 compared to its average of 17,615,270.
• Wall Street analysts have mixed views on Novo Nordisk A/S, with ratings ranging from "sell" to "buy," while the stock has an average rating of "Hold" and a consensus price target of $93.67.

Private Advisory Group LLC lessened its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 60.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,964 shares of the company's stock after selling 9,205 shares during the quarter. Private Advisory Group LLC's holdings in Novo Nordisk A/S were worth $414,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of NVO. Strategic Investment Solutions Inc. IL increased its holdings in shares of Novo Nordisk A/S by 2,727.3% during the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after purchasing an additional 300 shares during the period. Park Square Financial Group LLC bought a new position in shares of Novo Nordisk A/S during the 4th quarter worth about $29,000. Transce3nd LLC bought a new position in shares of Novo Nordisk A/S during the 4th quarter worth about $33,000. North Capital Inc. bought a new position in shares of Novo Nordisk A/S during the 1st quarter worth about $27,000. Finally, Copeland Capital Management LLC boosted its position in shares of Novo Nordisk A/S by 184.8% during the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after acquiring an additional 255 shares in the last quarter. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO traded up $1.16 during trading on Friday, reaching $48.23. The company had a trading volume of 34,710,384 shares, compared to its average volume of 17,615,270. Novo Nordisk A/S has a 52 week low of $46.90 and a 52 week high of $139.74. The stock has a market cap of $215.35 billion, a PE ratio of 14.27, a PEG ratio of 1.41 and a beta of 0.63. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.56 and a current ratio of 0.74. The business's 50 day moving average price is $69.64 and its 200-day moving average price is $72.95.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting analysts' consensus estimates of $0.92. The business had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. Analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Barclays reiterated an "equal weight" rating on shares of Novo Nordisk A/S in a research report on Wednesday. Dbs Bank lowered shares of Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. Hsbc Global Res lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday. Guggenheim lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. Finally, HSBC lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 price target on the stock. in a research report on Thursday. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $93.67.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.